Diagnostic Potential of the Salivary Biomarkers to Differentiate Statuses of Periodontitis

NCT ID: NCT05722613

Last Updated: 2023-02-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-05-01

Study Completion Date

2023-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Periodontitis is a chronic inflammatory disease characterized by both dysbiosis of oral microbiota and proinflammatory events involving both cells and mediators from innate and adaptive immunity. These events lead to chronic inflammation of periodontal soft and hard tissues sharing many features with other chronic inflammatory diseases. These events lead to chronic inflammation of periodontal soft and hard tissues sharing many features with other chronic inflammatory diseases. Chronic inflammation is driven by various mediators, of which a significant part is attributed to the interactions within cytokine networks. While proinflammatory cytokines, including interleukin (IL) -1α, IL-1β, TNF-α, IL-6, and IL-17, contribute to acute and chronic inflammation and tissue injury, a second group with antagonist effects is formed by cytokines such as IL-10

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Diagnosis of Periodontitis represents the backbone of a successful periodontal treatment since the entire treatment plan, prognosis, and maintenance directly depend on the quality and precision of periodontal diagnosis. Since periodontal diagnostics is still based on clinical and radiological parameters providing limited therapeutic guidance, biomarkers have been introduced for the first time within the new classification of periodontal and peri-implant conditions as a first step towards the adoption of precision medicine concepts in periodontology. Saliva, as part of oral fluids, is an optimal biological fluid that contains locally and systemically derived mediators of periodontal disease (proteins, genetic/genomic biomarkers such as DNA and mRNA, and various metabolites that originate from the host and the bacteria) to serve as the diagnostic tool for periodontitis. The collection of saliva is safe, non-invasive, and simple, and saliva can be collected repeatedly with minimum discomfort to the patient. Single biomarker detection may not be effective enough for accurate diagnoses without false-positive or false-negative results. Periodontitis is a disease that involves complex interactions between bacteria and the host immune system. The combination of the host and bacteria-derived biomarkers, which reflect inflammation, soft tissue destruction, and bone destruction together, may be helpful in the diagnosis

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Periodontitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

(Group A) periodontally healthy as a control

BOP \<10%, PPD ≤ 3mm, intact periodontium (no probing attachment loss).

No interventions assigned to this group

(Group B) periodontitis currently unstable

Generalized periodontitis, currently unstable (PPD ≥ 5mm or PPD at ≥ 4mm with BOP).

No interventions assigned to this group

(Group C)periodontitis currently stable .

Generalized periodontitis, currently stable (BOP \< 10 % PPD ≤4 mm and no BOP at 4mm sites)

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male and female systemically healthy patients.
2. Body mass index ≤ 30.
3. Have a minimum of 20 teeth with facial and lingual scorable surfaces.
4. Clinical criteria for periodontal health and periodontitis will be as follows :

1\. Healthy periodontium (Group A): BOP \<10%, PPD ≤ 3mm, intact periodontium (no probing attachment loss).

2\. Periodontitis groups are defined as : i. Interdental CAL is detectable at ≥2 non-adjacent teeth, or ii. Buccal or oral CAL ≥3 mm with pocketing \>3mm is detectable at ≥2teeth

Exclusion Criteria

1. Patients who refused to participate in the study.
2. Individuals with dental implants.
3. Previous history of extensive periodontal therapy preceding 6 months or currently under active periodontal treatment.
4. Patients receiving antibiotic treatment or immunosuppressant medication within the last 3 months
5. Pregnant or lactating mothers.
6. Any symptoms of recent acute illness, e.g., COVID-19.
7. Tobacco use.
8. Active orthodontic therapy

\-
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Baghdad

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Zainab Jalil Raheem

principal invstigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

zainab J Raheem, MSc

Role: PRINCIPAL_INVESTIGATOR

University of Baghdad

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Baghdad

Baghdad, , Iraq

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Iraq

References

Explore related publications, articles, or registry entries linked to this study.

Raheem ZJ, Abdulbaqi HR. Diagnostic Potential of Salivary Interleukin-1beta and IL-10 for Distinguishing Periodontal Health From Periodontitis and Stable From Unstable Periodontitis: A Case-Control Study. Int J Dent. 2024 Oct 15;2024:8006278. doi: 10.1155/2024/8006278. eCollection 2024.

Reference Type DERIVED
PMID: 39445112 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

527622

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.